PDCD1 and melanoma: The IGNYTE single-arm trial investigated the use of RP1 oncolytic virus in patients with PD-1-failed melanoma, demonstrating an ORR of 32.9% (including 15% CR), with a median duration of response of 33.7 months, comparing favorably to prior T-VEC data.